// App-Quantinova.ai

: Financial Impact of Imatinib Discontinuation in Brazil - a Real World Evidence Pharmacoeconomic Study in Chronic Myeloid Leukemia of a Private Institution

Researchers

Presenter

  • Renato Centrone

Principal Investigators

  • Marcelo Bellesso

  • Rodrigo Santucci Silva

  • Joyce Barreto Marques da Rosa Ferreira

  • Iohanã Gabriely Costa Oliveira

  • Luana Correa Travassos

  • Caroline Jorge Espadas

  • Tamyres Alves Gomes

  • Mariana Nascimento Caiaffo Rodrigues

  • Adelson Alves Silva

Medical Centers

  • Instituto Hemomed de Oncologia e Hematologia, São Paulo, Brazil

  • Instituto Hemomed, Sao Paulo, Brazil

  • Hemomed, Sao Paulo, Brazil

  • Instituto de Ensino e Pesquisa Sao Lucas - IEP Hemomed, Sao Paulo, SP, Brazil

Locations

  • Brazil

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Myelogenous Leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Imatinib

  • IkT001

Outcome

  • N/A

Study Design

  • Single Arm

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved